Posts

Biomanufacturing after COVID: keeping emergency readiness commercially viable

A recent BioSpace report says the biomanufacturing sector is shifting from COVID-era emergency mobilization toward maintaining readiness between crises. The pandemic showed that having factory capacity alone is not enough for a rapid vaccine response. Manufacturers also need transferable production processes, trained personnel, dependable raw materials, and coordinated supply networks. The central challenge is making preparedness economically sustainable. Companies and governments are exploring ways to keep facilities and capabilities viable through commercial production, advance procurement commitments, or reserved manufacturing capacity. Regional manufacturing and flexible CDMO networks may improve resilience, but still depend on technology transfer, reliable inputs, regulatory support, and enough ongoing demand to keep operations active. The report’s broader takeaway: preparedness must be built into routine commercial operations, rather than assembled only after an emergen...

Kodiak stock surges after two eye-drug candidates match Eylea in Phase 3

Merck licenses SciBrunch’s preclinical KRAS G12D drug in deal worth up to $2.13B

Merck and Daiichi withdraw lung-cancer drug filing after FDA pushback

Adicet reports encouraging early lupus CAR-T data as shares fall

ctDNA clearance: a promising early signal, not yet a definitive endpoint

Nektar wins $90 million jury award in dispute with Eli Lilly

Stipple Bio named to Endpoints 11 for its precision-oncology approach

FDA approves AbbVie’s once-daily Parkinson’s pill Juvmo

Oral SERDs after SERENA-4: narrower bets, not the end of the class

CARVYKTI five-year data point to durable remissions in multiple myeloma

Genentech signs $1.5B-plus AI bispecific-antibody oncology deal with Earendil

FDA approves Merck-Eisai Welireg-Lenvima combination for previously treated advanced kidney cancer